Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00002819
- Locations
- 🇺🇸
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 51
- Registration Number
- NCT00005059
- Locations
- 🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00003944
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 25
- Registration Number
- NCT00003846
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Biological Therapy in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- St. Luke's Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00002780
- Locations
- 🇺🇸
St. Luke's Medical Center, Milwaukee, Wisconsin, United States
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Hope Cancer Institute, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT00003562
- Locations
- 🇺🇸
Heartland Cancer Research Network, Kansas City, Kansas, United States
🇺🇸Bethany Medical Center, Kansas City, Kansas, United States
S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 68
- Registration Number
- NCT00003908
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸MBCCOP - University of South Alabama, Mobile, Alabama, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 30
- Registration Number
- NCT00003747
- Locations
- 🇬🇧
Mount Vernon Hospital, Northwood, England, United Kingdom
Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 38
- Registration Number
- NCT00003255
Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 584
- Registration Number
- NCT00003117
- Locations
- 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.